NCT02619513View on ClinicalTrials.gov

Effects of Dexmedetomidine Used in Continuous Thoracic Paravertebral Blocks

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Post-thoracotomy Pain Syndrome
Interventions
DRUG

Dexmedetomidine

Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.

DRUG

Ropivacaine

Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.

DEVICE

Mindray M7 series

Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.

Trial Locations (1)

510010

Department of Anesthesiology，Guangzhou Military Region General Hospital, Guangzhou

All Listed Sponsors
lead

Weifeng Tu

OTHER

NCT02619513 - Effects of Dexmedetomidine Used in Continuous Thoracic Paravertebral Blocks | Biotech Hunter | Biotech Hunter